|
Market Cap (10-Jun) $83,592,392 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (26-May) 45,932 (0.01%) (578th) |
|
52w High $0.480 |
52w Low $0.140 |
P/E 8.12 |
EPS -0.1 |
A news article has been posted about Paradigm Biopharmaceuticals on the AFR. The article was published around , on 23 August 2022 at 4:34pm.
The Chinese walls at brokerage Bell Potter may not be so thick as to be seen from space, but they do seem rather impenetrable. It’s already known Bell Potter loves speculative ASX-listed osteoarthritis treatment company Paradigm Biopharmaceuticals,
Read ArticlePAR was $1.28 at the close of trade on 22 August 2022
| Recent Articles about ASX:PAR | |
|---|---|
| 9-Jun | Phase 3 OA Trial Continues Following Formal DSMB 20% Safety ...
company-announcements.afr.com |
| 3-Jun | Appendix 3H - Notification of cessation of securities - AFR
company-announcements.afr.com |
| 2-Jun | Appendix 2A - Application for quotation of securities - AFR
company-announcements.afr.com |
| 2-Jun | Appendix 3Y - AFR
company-announcements.afr.com |
| 1-Jun | Appendix 3B - Proposed issue of securities - AFR
company-announcements.afr.com |
| 1-Jun | Results of Oversubscribed Share Purchase Plan - AFR
company-announcements.afr.com |
| 7-May | Paradigm Confirms 50% of Patients Dosed in Phase 3 OA Trial ...
company-announcements.afr.com |
| 1-May | Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth)
company-announcements.afr.com |
| 1-May | Appendix 2A - Application for quotation of securities - AFR
company-announcements.afr.com |
| 1-May | Form 603 - AFR
company-announcements.afr.com |
| Tracked |
Find all articles about Paradigm Biopharmaceuticals, including others on the AFR, on the media page.
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 